Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in Chinese Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT03523442Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in castration-resistant prostate cancer (CRPC), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentration of Apalutamide and Number of Participants with Adverse Events. Started Aug 2018; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03523442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523442.